Thank you for sharing!

Your article was successfully shared with the contacts you provided.

In September, when Manhattan federal district court Judge Kimba Wood dismissed a purported class action against Pfizer in which union health and welfare funds claimed misrepresentations involving the cholesterol-lowering drug Lipitor, she gave the plaintiffs an opportunity to re-plead most of the allegations, including their fraud and RICO claims. (Here’s a good analysis of her opinion by Russell Jackson at the Consumer Class Action and Mass Torts blog.) But the plans apparently didn’t hold out much hope that they could impress Wood on the second go-around. On Friday, both sides filed a stipulation indicating that the plaintiffs will drop the case and that Pfizer will not seek attorney fees or costs. The plaintiffs, third-party payors that covered a portion of the cost of Lipitor prescriptions for their members, alleged that Pfizer had misled doctors about the benefits and side effects of the medication. Wood ruled that the allegations in their complaint didn’t meet Iqbal pleading standards. Pfizer’s counsel in the case, Mark Cheffo of Skadden, Arps, Slate, Meagher & Flom, told us that Wood’s ruling called for plaintiffs to show in an amended complaint that they relied on specific alleged misrepresentations. But that would have made it tough for them to argue at the class certification state that class issues predominated, he said. “I think they saw the handwriting on the wall,” Cheffo said. Grant & Eisenhofer, known mostly for its work in securities class actions, took the lead on the case for the plaintiffs. We left a message with partner Stephen Grygiel, but didn’t hear back.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.